ClinicalTrials.gov
ClinicalTrials.gov Menu

Oseltamivir Pharmacokinetics in Morbid Obesity (OPTIMO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01002729
Recruitment Status : Completed
First Posted : October 27, 2009
Last Update Posted : August 3, 2011
Sponsor:
Collaborators:
Canadian Center for Vaccinology
Nova Scotia Health Authority
Dalhousie University
Hoffmann-La Roche
Information provided by:
IWK Health Centre

Brief Summary:
This trial asks the question: do people of much greater than average body weight need more of a drug called oseltamivir than current recommendations suggest. Oseltamivir is a drug given to people who have influenza, and currently is also being used to fight the new H1N1 influenza. Some people of larger than average body weight require larger amounts of drugs to see the same effects as others of an average body weight. No studies have ever been conducted looking at the possibility of oseltamivir being one of those drugs. Our Study's hypothesis states that those of an above average body weight will have different amounts of drug in their blood than those of people of normal body weight if they are given the normal amount prescribed for influenza. Our study will give oseltamivir to twenty people for 7 days. Half of the people will be of normal body weight and the others will be of a much higher than normal body weight. Using blood samples the investigators will determine if the amounts of oseltamivir are significantly lower in the blood of patients in the above normal body weight group.

Condition or disease Intervention/treatment Phase
Morbid Obesity Other: Patients with a BMI < 30 given Oseltamivir Other: Patients with a BMI > 40 given Oseltamivir Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oseltamivir Pharmacokinetics in Morbid Obesity
Study Start Date : November 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Oseltamivir


Intervention Details:
  • Other: Patients with a BMI < 30 given Oseltamivir
    Patients with a BMI < 30 given Oseltamivir
  • Other: Patients with a BMI > 40 given Oseltamivir
    Patients with a BMI > 40 given Oseltamivir


Primary Outcome Measures :
  1. Serum Drug Concentration [ Time Frame: 7 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females aged 18 to 55 years
  • Written informed consent
  • Subjects without medical history, physical finding or laboratory finding, which, in the opinion of the investigator, could pose a safety concern or interfere with the protocol.

Exclusion Criteria:

  • Allergy to oseltamivir
  • Blood donation within 3 months before oseltamivir administration
  • Medications that may interfere with the disposition of oseltamivir (e.g. probenecid)
  • Anemia
  • Estimated Creatinine clearance < 60 ml/min (As calculated by the modified Cockcroft Gault equation below) Creatinine Clearance= (140-Age) x 1.2 x Adjusted Body weight (x 0.85 if female) Serum Creatinine (umol/L)

Adjusted body weight = Ideal body weight + [0.4 (Actual Bodyweight-Ideal Body Weight)]

  • Gastrectomy
  • Enterectomy (or any other surgical procedure that would interfere with absorption)
  • Clinically significant haematological (RBC count, WBC count, WBC differential count, platelets count and haemoglobin level) or biochemical (ALT, AST, creatinine and urea) abnormalities as per the judgement of the investigator
  • Clinically significant cardiac conduction abnormality noted on baseline electrocardiogram.
  • Influenza like illness (fever and/or cough plus one of the following sore throat, fatigue, myalgia, headache) within 7 days of enrolment
  • Pregnancy
  • Inability to consume study meals provided due to special dietary requirements such as food allergies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002729


Locations
Canada, Nova Scotia
Human Vaccine Challenge Unit, IWK Health Center
Halifax, Nova Scotia, Canada, B3K 6R8
Sponsors and Collaborators
IWK Health Centre
Canadian Center for Vaccinology
Nova Scotia Health Authority
Dalhousie University
Hoffmann-La Roche
Investigators
Study Chair: Lucas M Thorne-Humphrey, BSC Pharm Dalhousie Unviersity, Captial District Health Authority

Publications of Results:
Responsible Party: McNeil, Shelly, IWK Health Sciences Center / Capital Distict Health Authority
ClinicalTrials.gov Identifier: NCT01002729     History of Changes
Other Study ID Numbers: RC91
First Posted: October 27, 2009    Key Record Dates
Last Update Posted: August 3, 2011
Last Verified: August 2011

Keywords provided by IWK Health Centre:
Oseltamivir Pharmacokinetics Obesity
Oseltamivir Pharmacokinetics in Obesity

Additional relevant MeSH terms:
Obesity
Obesity, Morbid
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action